We have a system where approved medicines are not readily available for patients: this is not a failure of science, but of the systems designed to facilitate access.
Europe’s health ambition is returning to the political agenda. With a focus on clinical trials, biotechnology and cardiovascular health, the Health Package signals Brussels’ intent to prioritize innovation, research and prevention as pillars of Europe’s competitiveness and resilience. But for many patients, one reality remains unchanged: access to innovative medicines remains too slow.
Today, European patients are waiting longer than ever to access new medicines, and the trend is moving in the wrong direction. The latest data from EFPIA’s WAIT indicator shows that the average wait time in Europe has increased to 597 days, 19 days longer than in 2025, and 93 days more compared with 2019.
